Chemoradiation in Nasopharyngeal Carcinoma: A 6-Year Experience in Tehran Cancer Institute

To determine the addition of value of neoadjuvant, concurrent and adjuvant chemotherapy to radiation in the treatment of nasopharyngeal carcinoma with regard to the overall survival (os) and disease free survival (dfs) within a six year period in tehran cancer institute. files of all patients with nasopharyngeal carcinoma treated by radiotherapy with or without concurrent chemotherapy in a curative setting in tehran cancer institute during the period of 1999-2005 were retrospectively reviewed.. a total of 103 patients with nasopharyngeal carcinoma had been treated during the study period with radiotherapy or chemoradiotherapy in our institute. there were 29 (28.2%) females and 74 (71.8%) males. the median age at the time of radiotherapy was 47 years old (range 9-75 years). the patients were followed 2 to 76 months with a median follow-up of 14 months. time of first recurrence after treatment was 3-44 months with a median of 10 months.. survival in 2 groups of patients treated with radiotherapy alone or chemoradiation did not have a significant difference (p>0.1). two-year survival in patients treated with or without adjuvant chemotherapy and had local recurrence after treatment did not have significant difference (p>0.1). two-year survival in patients with or without local recurrence after treatment did not have significant difference (p>0.1). a beneficial affect or a survival benefit of adjuvant/neoadjuvant chemotherapy and concurrent chemoradiation was not observed in iranian patients.